Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
This article was originally published in The Pink Sheet Daily
Executive Summary
Rival Medivation has a "Plan B" for Phase III if Sanofi-Aventis' cabazitaxel emerges as new standard of care as expected.
You may also be interested in...
Chart: Oncology: The Race Is On In HRPC; Sponsors Of Niche Oncologics Struggle
Sanofi-Aventis expects to complete a rolling NDA submission for its "home grown" novel taxoid Jevtana (cabazitaxel) by the end of the first quarter, Sanofi-Aventis Global Operations President Hanspeter Spek told a Feb. 10 earning call.
Unknown Timing of Lovenox Generics Complicates Sanofi-Aventis' Outlook
LONDON - Sanofi-Aventis CEO Chris Viehbacher appeared uncomfortable discussing the expected timing of generic competition to Lovenox (enoxaparin) during a Feb. 10 earnings call
Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration
As in its Dimebon collaboration with Pfizer, the biotech gets significant U.S. profit-sharing along with an option for co-promotion.